The association between statins exposure and peripheral neuropathy risk: A meta- analysis
The association between statins exposure and peripheral neuropathy risk: A meta- analysis
复制标题
他汀类药物暴露与周围神经病变风险之间的关联：荟萃分析
DOI：
10.1111/jcpt.13393
复制
发表时间：
--
影响因子：
2
通讯作者：
Ying Xie
中科院分区：
文献类型：
--
作者：
Miao Wang;Muqin Li;Ying Xie
他汀类药物是一种广泛应用的降脂药物，在多种心血管疾病的治疗中发挥着重要作用。随着使用范围和使用人数的增加，他汀类药物引起的周围神经病变已屡见报道。没有随机对照试验比较他汀类药物与周围神经病变风险之间的关系。因此，我们系统地回顾和Meta分析的观察性研究，评估他汀类药物对周围神经病变的风险的影响MethodsPubMed，Embase，科克伦图书馆数据库和Web of Science被用来搜索他汀类药物对多发性神经病变的影响，从开始到2020年12月3日。我们纳入了符合以下标准的研究：（i）随机对照试验，前瞻性或回顾性队列研究，检查他汀类药物与周围神经病变（PN）之间的关系。排除标准包括：与其他疾病或受试者相关的综述和研究;以及没有PN患病率数据的研究被排除。采用纽卡斯尔-渥太华量表（NOS）对纳入研究进行质量评估。使用Meta分析估计疾病风险。我们对随访持续时间、调整后（调整后RR与未调整RR）、样本量、研究设计和区域进行了亚组分析。结果和讨论共有9项独立研究评估了150 556例患者。在这项Meta分析中，我们发现他汀类药物暴露的PN无显著性增加（RR 1.26，95% CI（0.92 - 1.74））。我们的研究结果表明，他汀类药物暴露和周围神经病变的风险之间没有显着的关联。什么是新的和conclusionStatins暴露不影响周围神经病变的风险。本研究纳入的证据质量较低，但可以为临床医生提供有用的信息。
What is known and objectiveStatins are widely used lipid‐lowering drugs and play an important role in the treatment of many cardiovascular diseases. With the increase in the scope of use and the number of users, peripheral neuropathy caused by statins has been frequently reported. There are no randomized controlled trials comparing the relationship between statins and the risk of peripheral neuropathy. Therefore, we systematically reviewed and meta‐analysed observational studies evaluating the impact of statins on the risk of peripheral neuropathy.MethodsPubMed, Embase, the Cochrane Library databases and Web of Science were used to search the effects of statins on polyneuropathy from inception to 3 December 2020. We included studies that met the following criteria: (i) A randomized controlled trial, prospective or retrospective cohort study examining the relationship between statins and peripheral neuropathy (PN). Exclusion criteria included the following: Reviews and research related to other diseases or subjects; and studies without data on the prevalence of PN were excluded. Newcastle‐Ottawa scale (NOS) was used for quality assessment of included studies. Meta‐analysis was used to estimate the risk of disease. We conducted a subgroup analysis of duration of follow‐up, adjusted (adjusted RR vs. unadjusted RR), sample size, study design and region.Results and discussionA total of 9 independent studies assessing 150 556 patients were included in this analysis. In this meta‐analysis, we found that there was a nonsignificant increase of PN with statins exposure (RR 1.26, 95% CI (0.92‐1.74)). Our results revealed that there was no significant association between statins exposure and peripheral neuropathy risk.What is new and conclusionStatins exposure does not influence the risk of developing peripheral neuropathy. The quality of the evidence included in this study is low, but it can provide useful information for clinicians.